DPP4 and type 2 diabetes mellitus: Meanwhile, with the development of novel antidiabetic agents, including glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-dependent glucose transporter-2 (SGLT-2) inhibitors, the therapeutic alternatives for T2D are increasing (3).